Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency
Launched by UNIVERSITY HOSPITAL, MOTOL · Jul 9, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a dietary supplement called Geranylgeraniol to see if it can help patients with Mevalonate Kinase Deficiency, also known as HyperIgD syndrome. This condition is caused by a genetic issue that affects the body's immune system and can lead to inflammation. The trial aims to determine if Geranylgeraniol can safely improve the levels of certain important substances in the body that are lacking due to this condition.
The trial is currently looking for participants who are at least 12 years old and have been genetically confirmed to have Mevalonate Kinase Deficiency. They should be in generally good health aside from their condition and have normal liver function. Unfortunately, children younger than 12 cannot participate. Those who join the study can expect to take the supplement and be monitored for its effects. This research could provide valuable insights and potentially lead to better treatment options for people living with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients older than 12 years with genetically confirmed MVK deficiency
- • Overall good clinical status apart from the clinical presentation of the MVK deficiency
- • Normal liver tests
- • Compliance with the study protocol
- Exclusion Criteria:
- • • Children below 12 years
About University Hospital, Motol
University Hospital Motol is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical trials. Located in Prague, Czech Republic, the hospital is affiliated with Charles University and serves as a key institution for medical education and training. With a robust focus on patient-centered care, University Hospital Motol conducts a wide range of clinical studies across various specialties, aiming to improve treatment outcomes and enhance the understanding of complex medical conditions. The hospital's commitment to excellence in research, combined with its state-of-the-art facilities and multidisciplinary expertise, positions it at the forefront of clinical trial initiatives in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Prague, , Czechia
Patients applied
Trial Officials
Anna Šedivá, Mgr
Principal Investigator
University Hospital, Motol
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported